# Corcept Therapeutics share price today (Corcept Therapeutics Incorporated, CORT)

> Corcept Therapeutics Incorporated's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CORT · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/cort

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: $71.63 (−2.8% in a year)
- P/E: 53.9×, over 4.6 years
- Revenue (Jun 2026): $256 M (+31.7% on a year ago)
- Profit (Jun 2026): $42.1 M (+21.8% on a year ago)
- Operating margin: 16.1% (+2.4 points on a year ago)
- ROE: 15%, FY25
- ROIC: 25.2%, against a 7.3% cost of capital: +17.9 points

The main question: the share price moved −2.8% in a year while yearly earnings per share moved −33.3%. The difference came from the market paying a higher multiple. ## What is the Corcept Therapeutics share price today? Corcept Therapeutics Incorporated's share price was $71.63 at the close on 5 November 2026. It has been moving sideways for 1 week. That is 5.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between $32 and $122, and at that close it sat 44% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 3 weeks running. Over the last 10 years the share price moved +1,092% while the S&P 500 moved +245%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 16 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Corcept Therapeutics pay? Corcept Therapeutics Incorporated pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Corcept Therapeutics on? Corcept Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Corcept Therapeutics profitable? Corcept Therapeutics Incorporated earned $42.1 M of net profit in the Jun 2026 quarter, +21.8% on the same quarter a year earlier. Full-year FY25 profit was $98.2 M. Over 4 years profit has grown −3.4% a year on average. That is 16.5% of the quarter's revenue. The same quarter a year earlier earned $34.6 M. 1 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $98.2 M (−29.7% on the year before). Why profit moved: revenue changed +31.7% on a year earlier and the margin moved +2.4 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed −78.0% and revenue +15.3%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Corcept Therapeutics make, and is it growing? Corcept Therapeutics Incorporated reported $256 M of revenue in the Jun 2026 quarter, +31.7% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 20.1% a year on average. The last full year, FY25, came in at $761 M. The last four reported quarters add to $831 M. FY25 revenue was $761 M, +12.8% on the year before. Recent pace: the last four quarters grew +15.3% on average, against 20.1% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +16.0%, against +20.8% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −58.9%, against −34.1% a year (rolling over). ## How much of every $100 of sales does Corcept Therapeutics keep? Corcept Therapeutics Incorporated's operating margin was 16.1% in the Jun 2026 quarter, 2.4 percentage points higher than the same quarter a year ago. Across 5 years it has been between 5.9% and 34.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +2.4 percentage points on the year while gross margin changed +0.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Corcept Therapeutics' profit turning into cash? Over the last 3 years, 136% of Corcept Therapeutics Incorporated's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $142 M of operating cash against $98.2 M of profit. After $211 K of spending on assets, $142 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Corcept Therapeutics' cash go? Corcept Therapeutics Incorporated does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.5 M on assets over the last 3 years. Averaged over those years that is 0.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $2.5 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Corcept Therapeutics' P/E ratio, and how does it compare with its own history? Corcept Therapeutics Incorporated's P/E is 53.9×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −33.3% while the price moved −2.8%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved +40.9% a year; about −19.7% a year came from earnings growth and about +60.6 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Corcept Therapeutics business getting better or worse? Corcept Therapeutics Incorporated's business is getting worse. Profit and EPS growth are shrinking: profit growth is −58.9% in the latest quarter, against +54.6% at its best in 12 quarters, with ROCE falling at 0.9%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Corcept Therapeutics earn on its capital? Corcept Therapeutics Incorporated earned a ROE of 15% in FY25. Its return on capital used (ROIC) is 17.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 12.9% net margin and 0.91× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 12.9% net margin × 0.91× asset turnover × 1.29× leverage (assets divided by equity) ≈ 15.1% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 25.2% − 7.3% = +17.9 percentage points. The 7.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 25.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 15.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Corcept Therapeutics have too much debt? Corcept Therapeutics Incorporated has total debt of $9.4 M against shareholder equity of $706 M as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.00 in FY21 to 0.01 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Corcept Therapeutics shareholding pattern? 8.9% of Corcept Therapeutics Incorporated's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 5.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Corcept Therapeutics from balance-sheet trouble? For Corcept Therapeutics Incorporated, the Z-score is 25.60. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 25.60 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Corcept Therapeutics rank in its industry? There is no score against its industry: Corcept Therapeutics Incorporated is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Corcept Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Corcept Therapeutics in size? Corcept Therapeutics is the 31st largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: ImmunityBio, Inc., TG Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc. Just below it: Cytokinetics, Incorporated, ABIVAX Société Anonyme and Caris Life Sciences, Inc. ### Biotechnology companies close in size

1. [ImmunityBio, Inc.](https://www.sectoralpha.in/us/stocks/ibrx) $8.5 billion
2. [TG Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/tgtx) $8.2 billion
3. [Arrowhead Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/arwr) $8.1 billion
4. Corcept Therapeutics Incorporated $7.8 billion
5. [Cytokinetics, Incorporated](https://www.sectoralpha.in/us/stocks/cytk) $7.7 billion
6. [ABIVAX Société Anonyme](https://www.sectoralpha.in/us/stocks/abvx) $7.6 billion
7. [Caris Life Sciences, Inc.](https://www.sectoralpha.in/us/stocks/cai) $7.5 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [IDACORP, Inc.](https://www.sectoralpha.in/us/stocks/ida) $8.7 billion · Utilities - Regulated Electric
2. [Westlake Corporation](https://www.sectoralpha.in/us/stocks/wlk) $8.7 billion · Specialty Chemicals
3. Corcept Therapeutics Incorporated $8.7 billion
4. [Columbia Banking System, Inc.](https://www.sectoralpha.in/us/stocks/colb) $8.7 billion · Banks - Regional
5. [Rexford Industrial Realty, Inc.](https://www.sectoralpha.in/us/stocks/rexr) $8.7 billion · REIT - Industrial

## What else do people ask about Corcept Therapeutics? ### What were Corcept Therapeutics's latest quarterly results? Corcept Therapeutics Incorporated reported revenue of $256 M and net profit of $42.1 M for the Jun 2026 quarter. Revenue rose 31.7% and profit rose 21.8% compared with a year earlier. Earnings per share were $0.36. The operating margin was 16.1%, 2.4 percentage points higher than a year earlier (as of 5 November 2026). ### What is Corcept Therapeutics's market cap? Corcept Therapeutics Incorporated's market capitalisation is $7.8 B at a stock price of $71.63. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Corcept Therapeutics performing? Corcept Therapeutics Incorporated's share price has been moving sideways for 1 weeks. In its latest quarter, revenue rose 31.7% and profit rose 21.8% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 3 weeks running (as of 5 November 2026). ### Will Corcept Therapeutics's stock price go up? This page does not forecast Corcept Therapeutics Incorporated's stock price. What it shows instead: the stock price is $71.63, and it has been moving sideways for 1 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is Corcept Therapeutics in its business cycle? Corcept Therapeutics Incorporated's FY25 operating margin was 5.9%, against a 5-year range of 5.9% to 34.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 16.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Corcept Therapeutics story? The main question: the share price moved −2.8% in a year while yearly earnings per share moved −33.3%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Corcept Therapeutics a stock worth studying right now? What the numbers show: Corcept Therapeutics Incorporated's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.